FY2024 EPS Estimates for Immunome Lowered by Leerink Partnrs

Immunome, Inc. (NASDAQ:IMNM) – Stock analysts at Leerink Partnrs dropped their FY2024 earnings per share estimates for shares of Immunome in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings of ($2.23) per share for the year, down from their previous estimate of ($1.63). The consensus estimate for Immunome’s current full-year earnings is ($2.13) per share. Leerink Partnrs also issued estimates for Immunome’s Q4 2024 earnings at ($0.81) EPS, FY2025 earnings at ($4.17) EPS, FY2026 earnings at ($4.36) EPS and FY2027 earnings at ($3.97) EPS.

Several other brokerages have also recently commented on IMNM. Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a report on Friday, October 25th. Piper Sandler reduced their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Finally, Stephens began coverage on shares of Immunome in a research report on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome currently has a consensus rating of “Buy” and a consensus target price of $28.83.

Immunome Trading Down 4.7 %

Shares of IMNM stock opened at $9.44 on Monday. Immunome has a 1-year low of $6.93 and a 1-year high of $30.96. The stock has a market cap of $588.93 million, a price-to-earnings ratio of -1.16 and a beta of 1.82. The stock has a 50-day moving average of $13.02 and a 200-day moving average of $13.75.

Hedge Funds Weigh In On Immunome

Several institutional investors have recently made changes to their positions in the stock. Redmile Group LLC increased its position in Immunome by 26.0% in the 1st quarter. Redmile Group LLC now owns 4,889,554 shares of the company’s stock valued at $120,674,000 after buying an additional 1,010,139 shares in the last quarter. FMR LLC grew its stake in Immunome by 0.3% in the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock valued at $61,765,000 after acquiring an additional 13,757 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Immunome by 10.3% during the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after acquiring an additional 324,614 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Immunome by 113.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock worth $55,425,000 after purchasing an additional 1,194,451 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Immunome by 16.1% in the 1st quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock worth $49,847,000 after purchasing an additional 279,712 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Insider Buying and Selling at Immunome

In other Immunome news, CFO Max Rosett sold 14,380 shares of the firm’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $16.01, for a total value of $230,223.80. Following the completion of the sale, the chief financial officer now directly owns 47,476 shares in the company, valued at approximately $760,090.76. This trade represents a 23.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 8.60% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.